Enanta Pharmaceuticals (ENTA) Stock Price, News & Analysis

6 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Enanta Pharmaceuticals in the last year. There are currently 1 sell rating, 3 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" ENTA shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in ENTA, but not buy additional shares or sell existing shares.
View ENTA analyst ratings or view top-rated stocks.

6 analysts have issued 12-month target prices for Enanta Pharmaceuticals' shares. Their ENTA share price targets range from $11.00 to $28.00. On average, they expect the company's share price to reach $19.33 in the next twelve months. This suggests a possible upside of 48.9% from the stock's current price.
View analysts price targets for ENTA or view top-rated stocks among Wall Street analysts.

Enanta Pharmaceuticals' stock was trading at $9.41 at the start of the year. Since then, ENTA shares have increased by 37.9% and is now trading at $12.98.
View the best growth stocks for 2024 here.

The company is scheduled to release its next quarterly earnings announcement on Monday, May 13th 2024.
View our ENTA earnings forecast.

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) issued its quarterly earnings results on Wednesday, February, 7th. The biotechnology company reported ($1.58) earnings per share for the quarter, missing the consensus estimate of ($1.18) by $0.40. The biotechnology company earned $18 million during the quarter, compared to the consensus estimate of $22.74 million. Enanta Pharmaceuticals had a negative trailing twelve-month return on equity of 60.38% and a negative net margin of 187.77%.

ETFs with the largest weight of Enanta Pharmaceuticals (NASDAQ:ENTA) stock in their portfolio include Amplify Treatments, Testing and Advancements ETF (GERM).Invesco Nasdaq Future Gen 200 ETF (QQQS).

5 employees have rated Enanta Pharmaceuticals Chief Executive Officer Jay R. Luly on Glassdoor.com. Jay R. Luly has an approval rating of 100% among the company's employees. This puts Jay R. Luly in the top 10% of approval ratings compared to other CEOs of publicly-traded companies. 86.0% of employees surveyed would recommend working at Enanta Pharmaceuticals to a friend.

Based on aggregate information from My MarketBeat watchlists, some companies that other Enanta Pharmaceuticals investors own include Cronos Group (CRON), Dollar Tree (DLTR), AbbVie (ABBV), Gilead Sciences (GILD), Intercept Pharmaceuticals (ICPT), NVIDIA (NVDA), Netflix (NFLX), GW Pharmaceuticals (GWPH), Micron Technology (MU) and Zoetis (ZTS).

Enanta Pharmaceuticals' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Hennion & Walsh Asset Management Inc. (0.06%). Insiders that own company stock include Brendan Luu, Bruce L A Carter, Jay R Luly, Nathalie Adda, Paul J Mellett, Scott T Rottinghaus, Terry Vance and Yat Sun Or.
View institutional ownership trends.

Shares of ENTA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.